Ultra short pre-seasonal subcutaneous immunotherapy and pre-coseasonal sublingual immunotherapy for pollen allergy: an evaluation of patient's preference in real life.

摘要: Background Specific immunotherapy (SIT) efficacy and safety by subcutaneous (SCIT) sublingual (SLIT) route is supported literature data. Pre-coseasonal treatment currently the more accepted option for pollen in terms of costs patient's compliance. This retrospective study evaluated preference concerning or pre-coseasonal treatment. Materials methods We 145 patients (79 males, 66 females, age ranging from 14 to 69 years), suffering moderate-severe rhino-conjunctivitis mild bronchial asthma with homogeneous characteristic according allergic disease severity. proposed either SLIT, extracts different producers, SCIT Pollinex 4 (Allergy Therapeutics, Worthing, UK), a product designed ultra-short administration injections, highlighting each kind SIT major practical advantages burdens. Results Of patients, 72 chose 73 SLIT. SCIT-treated received total 90 vaccines (18 had double course SCIT). SLIT-treated 87 (14 SLIT). In group, there were 49 males 23 females; SLIT 30 43 females. Mean was 36.5 years group 28.5 group. Males preferred (49 patients) females (43 patients). No severe reaction observed Conclusion Patients are active subjects decisional process. Trying apply real life indications coming guidelines about an important matter. our ultra short schedule similarly preferred.